SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

SELLASs upcoming Phase 3 REGAL leukemia-trial readout is the dominant catalyst, with traders focused on whether GPS meets its survival endpoint. Bullish anticipation of a major revaluation and short squeeze is countered by concerns that the binary results could disappoint; sharp price swings have also fueled claims of short pressure and manipulation, which remain speculation.

Unity Software, Inc. engages in the developing video gaming software. It also provides software solutions to create, run and monetize interactive, real-time two-dimensional and three-dimensional content for mobile phones, tablets, consoles, and augmented and virtual reality devices. Its platform is used by developers, artists, and designers to build content for gaming, film, retail, automotive, architecture, engineering, and construction industries. The company was founded by Joachim Ante and David Helgason in 2004 and is headquartered in San Francisco, CA.

Unity Software Inc

Reported preliminary takeover discussions involving Silver Lake and Saudi Arabias PIF are driving attention, with traders debating whether a potential offer would undervalue Unity and whether a deal will happen. The debate is reinforced by strong Q3 results, first-ever GAAP profitability and rapid Vector advertising growth, which some investors cite as reasons Unity may be worth more independently.

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of therapies for metabolic and endocrine disorders. The company was founded by Brian Lian and Michael A. Dinerman on September 24, 2012 and is headquartered in San Diego, CA.

Viking Therapeutics Inc

Heavy trading and a sharp move have reignited speculation about a potential Big Pharma partnership or buyout, with Novo often named as a possible counterparty; no deal is confirmed. Traders are divided between seeing the activity as positioning around VK2735 and upcoming obesity-conference presentations and dismissing it as another rumor-driven pump amid a long wait for Phase 3 results.

Summit Therapeutics, Inc. is a biopharmaceutical company, that focuses on the discovery, development, and commercialization of patient, physician, caregiver, and societal-friendly medicinal therapies intended to improve quality of life, increase potential duration of life, and resolve serious unmet medical needs. The firm conducts clinical programs focusing on Clostridioides Difficile Infection (CDI). Its lead product, Ridinilazole, is an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment of CDI. The company was founded in 2003 and is headquartered in Miami, FL.

Summit Therapeutics Inc

Summits FDA decision on ivonescimab for EGFR-mutated lung cancer is the dominant catalyst, with traders debating approval versus a possible rejection or delay. The debate centers on the drugs strong progression-free-survival results and favorable survival trend versus the FDAs stated need for statistically significant overall-survival evidence, driving uncertainty around the binary outcome.

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

Jensen Huangs departure and uncertainty over Nvidias next CEO are driving debate, with traders weighing reports that the board approached Arm CEO Rene Haas against speculation Huang could return. Bulls view the selloff as a buying opportunity, while bears point to leadership uncertainty and unresolved China-related export scrutiny as risks.

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.

Novo Nordisk - ADR

Novo Nordisk A/S

Novos stronger-than-expected quarterly performance and raised outlook, attributed in the discussion to robust oral Wegovy demand, have fueled renewed interest in the shares. Bulls see the pill and international expansion as growth drivers, while skeptics point to Lillys competition, pricing pressure and execution concerns.

Zevra Therapeutics, Inc. is a commercial-stage rare disease company that combines science, data and patient needs to create therapies for diseases with limited or no treatment options. The firm focuses on the treatment of rare neurological and sleep conditions such as certain Urea Cycle Disorders, Niemann Pick Disease Type C and Idiopathic Hypersomnia. The company receives royalties for AZSTARYS from its commercial partner Corium. The company was founded by Christal M. M. Mickle and Travis C. Mickle on October 30, 2006 and is headquartered in Celebration, FL.

Zevra Therapeutics Inc

Zevra shares are under pressure after the European regulator reaffirmed its negative opinion on arimoclomol (Miplyffa) for Niemann-Pick disease type C, with the European Commissions final decision still pending. Traders are divided on the selloff: some see the setback as largely expected and an overreaction given the existing U.S. business, while others fault management and view the lost European opportunity as significant.

Newsmax Inc. is a holding company, which engages in television broadcasting and multi-platform content publishing that produces original news and editorial content for consumers through various media outlets, including TV new channels, digital and print publications. It operates through the Broadcasting and Digital Segments. The Broadcasting segment produces and licenses news, business news and lifestyle content for distribution through both MVPDs and free OTT streaming platforms. The Digital segment is composed of Newsmax.com and affiliated websites. The company was founded by Christopher Ruddy in 1998 and is headquartered in Boca Raton, FL.

Newsmax Inc. - Ordinary Shares - Class B

Newsmax Inc

Newsmaxs better-than-expected Q3 results, with strong revenue growth and a return to profitability, are driving attention. Traders are reacting bullishly and discussing further momentum or a squeeze, while some caution that a one-time payment boosted reported revenue and question the quality of recurring earnings.

iShares Trust - iShares 20+ Year Treasury Bond ETF

iShares 20+ Year Treasury Bond ETF

A softer-than-expected monthly PPI reading is being weighed against accelerating year-over-year producer inflation, keeping traders focused on possible Fed rate hikes and elevated Treasury yields that pressure TLT. The community is split between expecting further bond weakness and viewing a recession or eventual rate cuts as a longer-term tailwind.

HawKeye 360, Inc. engages in the provision of defense technology. It offers spectrum monitoring, maritime intelligence, air defence radar monitoring, GNSS interference detection, and communications mapping. Its costumers include a wide range of commercial, government and international entities. The company was founded by Charles T. Clancy, Robert G. McGwier, Chris DeMay and John Serafini in 2015 and is headquartered in Herndon, VA.

HawkEye 360 Inc.

Record Q3 results and raised full-year guidance have drawn attention, with traders pointing to international contract growth and demand for HawkEye 360s defense and signals-intelligence services. Sentiment is largely bullish around the strong share move and trading volume, while claims of institutional accumulation remain speculation.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Autodesk Shrugs Off Macro Vagaries After Q1 Beat: Analysts, Retail Turn Stick To Bullish Stances

Equity

Following Q1 results, Oppenheimer analysts upped their price target for the Autodesk stock to $350 from $300 and maintained an ‘Outperform’ rating.


Autodesk Says Willing To Review Starboard Slate As Proxy War Heats Up: Retail Mood Worsens

Replying to issues raised by Starboard, Autodesk said it has been taking decisive actions to drive growth, significantly expand operating margin, generate robust cash flow and continue innovating for customers.


Autodesk Activist Drama Unfolds As Starboard Reportedly Gears Up For Proxy Fight: Retail Traders Divided

Starboard is reportedly considering nominating a minority slate of director candidates ahead of Autodesk’s annual shareholders’ meeting.


ProShares Trust - ProShares S&P Kensho Smart Factories ETF

Bullish Sentiment

Autodesk, Inc. (ADSK) stock received a price target boost after the engineering design software maker announced a first-quarter beat.Oppenheimer analysts upped their price target for the Autodesk stock to $350 from $300 and maintained an ‘Outperform’ rating, The Fly reported. The analysts called the results “solid” and expressed comfort at the company reiterating its guidance in a&nbsp;challenging macro/industrial backdrop.The research firm said the company embedded incremental macro conservatism in the guidance even as it flagged no material change in demand through May.Autodesk’s key quarterly metrics for the first quarter of the fiscal year 2026 are as follows:<ul><li>Adj. earnings per share (EPS): $2.29 Vs. $2.15 consensus</li><li>Revenue: $1.63B (up 15% YoY) Vs. $1.61B consensus</li><li>Billings: $1.43B (up 29% YoY)</li></ul>&nbsp;"Q1 was another strong quarter. We have not seen changes in overall business momentum when compared to recent quarters," said Janesh Moorjani, Autodesk CFO.The executive said the guidance for the second quarter and the rest of the fiscal year included currency movements since February, partly offset by additional caution in growth assumptions reflecting greater macroeconomic uncertainty.Autodesk guided second-quarter adjusted EPS and revenue to a range of $2.44-$2.48 and $1.72 billion-$1.73 billion, respectively. Analysts, on average, estimate $2.39 and $1.71 billion, respectively.On Stocktwits, retail sentiment toward Autodesk stock was ‘extremely bullish’ (90/100) by late Thursday, with the message volume at ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:618/51;" src="https://news.stocktwits-cdn.com/Screenshot_2025_05_23_at_3_51_37_AM_png_9f2ad510f9.webp" alt="Screenshot 2025-05-23 at 3.51.37 AM.png" width="618" height="51"><figcaption>ADSK sentiment and message volume as of 3:52 a.m. ET, May 23 | source: Stocktwits</figcaption></figure>A bullish user said Autodesk had a much better earnings report and forecast&nbsp;than Snowflake, Inc. (SNOW). While noting that Snowflake went up by 13.4% on Thursday, they predicted Autodesk stock&nbsp;would hit&nbsp;$334 on Friday.<stembedurl>https://stocktwits.com/AIIAAIIA_88/message/615613366</stembedurl>Another user feared the guidance could bring the stock down, but expressed faith that it&nbsp;would go up in the long run.<stembedurl>https://stocktwits.com/nj8263/message/615611228</stembedurl><a href="https://stocktwits.com/symbol/ADSK">Autodesk stock </a>rose 3.32% to $304.78 in the after-hours session, but it is down marginally for the year. During the quarter, the company faced a proxy war from activist investor Starboard over the stock's underperformance.For updates and corrections, email newsroom[at]stocktwits[dot]com.Read Next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/apple-retail-traders-lose-faith-amid-7-day-losing-streak/ch0Q9ynRbqh">Apple Retail Traders Lose Faith As Market-Cap Trails Microsoft, Nvidia Amid 7-Day Losing Streak</a>

In this photo illustration, the Autodesk Software company logo seen displayed on a smartphone.

Following Q1 results, Oppenheimer analysts upped their price target for the Autodesk stock to $350 from $300 and maintained an ‘Outperform’ rating.

Autodesk Inc.

Pacer Funds Trust - Pacer BlueStar Engineering the Future ETF

ProShares S&P Kensho Smart Factories ETF

Up more than 1%

Flat to up 1%

Flat to down 1%

Down more than 1%

What do you think the S&amp;P 500&#39;s ($SPY) return will be next week?

Feed

News

Sentiment

Fundamentals

Info

MAKX ProShares S&P Kensho Smart Factories ETF

Fundamentals

Latest MAKX News